Hormone pill could unlock diagnosis of rare oxytocin deficiency in teens

NCT ID NCT07568509

Recruiting now Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether a single dose of a hormone pill can help diagnose oxytocin deficiency in young people with hypopituitarism. Researchers will give the pill to 20 participants and measure oxytocin-related substances in blood and saliva. The goal is to develop a simple provocation test for a condition that currently lacks a standard diagnostic method.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Norethindrone Acetate-Ethinyl Estradiol (a hormone pill)
What this could lead to: If successful, this could lead to a reliable diagnostic test for oxytocin deficiency, helping doctors identify and treat this condition in young people.
What could go wrong: This is a very early, small pilot study with only 20 participants. The test may not work as hoped, and results may not apply to everyone with hypopituitarism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARGININE VASOPRESSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Insipidus, Neurogenic hypopituitarism neurohypophyseal diabetes insipidus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARGININE VASOPRESSIN DEFICIENCY HYPOPITUITARISM OXYTOCIN DEFICIENCY PEDIATRIC DISEASE

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.